Katamine—once an illegal street drug now used in therapy—is replacing traditional perks like gym memberships and days off to treat employees, like Matt Gutman, with anxiety and depression.
What used to be illegal party drugs, then LA elite-only psychedelic therapies, are making their way into the research lab, mainstream medicine and now the workplace. A study in last month’s Journal of the American Medical Association reported that after researchers administered the psychedelic drug, psilocybin, in a single-dose, randomized clinical trial, it resulted in a significant reduction in depression among the participants. And there’s more. A burgeoning body of research shows that the trance-induced effects of the psychedelic, ketamine—used in conjunction with psychotherapy—has significant mental health benefits.
